cardiovascular events /outcomes
Showing 1 - 25 of >10,000
Triglyceride-Glucose Index on Cardiovascular Outcomes in
Not yet recruiting
- Major Cardiovascular Events
- Triglyceride glucose index TyG
- (no location specified)
Oct 6, 2023
Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)
Not yet recruiting
- Arteriosclerosis
- Hypercholesterolaemia
- MK-0616
- Placebo
- (no location specified)
Aug 17, 2023
Pollutants in Atherosclerotic Plaque and Cardiovascular Events
Recruiting
- Atherosclerosis
- analysis of carotid atherosclerotic plaque
-
Naples, ItalyCelestino Sardu
Jun 12, 2023
PASS to Assess Cardiovascular and Cerebrovascular Events in COPD
Not yet recruiting
- Chronic Obstructive Pulmonary Disease
- Observational retrospective data collection
- (no location specified)
Dec 14, 2022
Obstructive Hypertrophic Cardiomyopathy
Completed
- Microvascular Dysfunction
- +2 more
-
Beijing, Beijing, ChinaFuwai Hospital, China National Center for Cardiovascular Disease
Jan 11, 2023
Outcomes After Gastrointestinal Bleeding
Recruiting
- Gastrointestinal Hemorrhage
- Cardiovascular Diseases
-
Hamilton, Ontario, CanadaHamilton Health Sciences, PHRI
Sep 29, 2022
Acute Heart Failure, Heart Failure Trial in Boston (Dapagliflozin, Placebo)
Recruiting
- Acute Heart Failure
- Heart Failure
- Dapagliflozin
- Placebo
-
Boston, MassachusettsTIMI Study Group
Dec 9, 2021
Cardiovascular Diseases, Uric Acid Trial (Allopurinol 200 mg, Optional intervention)
Not yet recruiting
- Cardiovascular Diseases
- Uric Acid
- Allopurinol 200 mg
- Optional intervention
- (no location specified)
Jul 5, 2023
Obesity Trial (Naltrexone-Bupropion (NB) Combination, Placebo)
Not yet recruiting
- Obesity
- Naltrexone-Bupropion (NB) Combination
- Placebo
- (no location specified)
Oct 18, 2023
Frailty on Cardiovascular Events and Mortality in COPD.
Not yet recruiting
- Role of Frailty in COPD
- Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months
- (no location specified)
Jun 19, 2023
Cardiovascular Diseases Trial in Nassau (Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte))
Recruiting
- Cardiovascular Diseases
- Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
-
Nassau, The Bahamas, BahamasThe Partners Clinical Research Centre at The Medical Pavilion
Oct 17, 2023
Coronary Artery Disease Trial in Sacramento (device, behavioral, other)
Recruiting
- Coronary Artery Disease
- LiveCare
- +2 more
-
Sacramento, CaliforniaUniversity of California, Davis Medical Center Division of Cardi
Oct 27, 2023
Inclisiran on Major Adverse Cardiovascular Events in French
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran sodium
- +3 more
- (no location specified)
Jul 26, 2023
Suspicion of Cardiovascular Events on Immunecheckpoint
Recruiting
- Cancer
- +3 more
- No intervention for research purposes only
-
Paris, FranceIntitut Mutualiste Montsouris
Mar 23, 2023
Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)
Not yet recruiting
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Placebo in 1.5ml
- (no location specified)
Feb 13, 2023
Primary Cardiovascular Events Using the Multimarker Approach
Completed
- Cardiovascular Diseases
- +4 more
- measurement of multiple biomarkers
- (no location specified)
Jan 19, 2023
Atherosclerotic Cardiovascular Disease Trial in Worldwide (Placebo, Olpasiran)
Recruiting
- Atherosclerotic Cardiovascular Disease
- Placebo
- Olpasiran
-
Huntsville, Alabama
- +83 more
Feb 1, 2023
Troponin to Detect Major Cardiovasculaire Advserse Events on
Recruiting
- Cancer
- +2 more
- No intervention
-
Paris, FranceInstitut Mutualiste Montsouris
Aug 22, 2023
Shock Factor: Effects of Surprise on Cardiovascular Responses.
Recruiting
- Physiologic Responses to Surprise Events
- Surprise events
-
Keswick, Ontario, CanadaPlaySafe Productions
Dec 15, 2022
Diabetes, Type 2, Major Adverse Cardiac Events Trial in Hangzhou (CGM)
Not yet recruiting
- Diabetes Mellitus, Type 2
- Major Adverse Cardiac Events
- CGM
-
Hangzhou, Chinathe Second Affiliated Hospital Zhejiang University Schoolof Medi
Sep 23, 2023
Novel Cardiovascular Biomarkers in Patients With Kidney Disease
Not yet recruiting
- Haemodialysis Complication
- Major Adverse Cardiac Events
- Cardiac Biomarkers
- +2 more
- (no location specified)
Sep 14, 2023
Acute Cardiovascular Adverse Events Occuring in Children Treated
Not yet recruiting
- Malignancies
- +2 more
- use of anticancer drugs in monotherapy or in combination therapy
- (no location specified)
Oct 27, 2022
Cardiovascular Diseases Trial in Shatin (TQJ230, Placebo)
Active, not recruiting
- Cardiovascular Diseases
- TQJ230
- Placebo
-
Shatin, Hong KongThe Chinese University of Hong Kong
Sep 16, 2022
Ferroptosis in COPD COPD With/Without Risk of Cardiovascular
Recruiting
- COPD Exacerbation
- Non-interventional study
-
Santander, Cantabria, SpainHospital Universitario Marqués de Valdecilla
Oct 25, 2023
Intraoperative Adverse Events in Robotic Radical Gastrectomy for
Completed
- Gastric Cancer
- robotic surgery
- (no location specified)
Aug 11, 2023